Drug Trial Radar · NCT05882734
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
61
Actual
Start
Sep 13, 2023
Primary completion
Jul 15, 2026
Study completion Jul 15, 2026
Sponsor
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany
- First posted
- May 31, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an Open-label, multicenter clinical study conducted in two Phases to establish the efficacy, safety, tolerability, and pharmacokinetics of the ataxia telangiectasia mutated and Rad3-related protein kinase (ATR) inhibitor Tuvusertib in Combination with Cemiplimab in Participants with Non-Squamous Non-Small Cell Lung Cancer (nsqNSCLC) that has Progressed on Prior Anti-PD-(L)1 and Platinum-based Therapies..
Conditions
- Non-Small Cell Lung Cancer
Interventions
M1774Drug
In Phase 1b, M1774 will be administered as dosing regimen 1 or dosing regimen 2 until disease progression, death discontinuation criteria or any other reason. The selected dosing regimen of M1774 will be administered in all arms of Phase 2a.
CemiplimabDrug
Cemiplimab will be administered as an intravenous infusion every 3 weeks in all arms of Phase 1b and Phase 2a until disease progression, death discontinuation criteria or any other reason.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b/Phase 2a: Confirmed Overall response (OR) According to Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 As assessed by InvestigatorTime frame: Time from randomization to final assessment or until progression disease, death, discontinuation criteria approximately up to 3 years and 2 months
- Phase 1b: Number of Participants With Adverse Events (AEs) and Treatment-related AEsTime frame: Time from randomization to final assessment at end of safety follow-up visit approximately up to 3 years and 2 months
Locations
54 sites in 8 countries. Site status is shown where the registry gives one.
UCLA Hematology and Oncology - Santa Monica
Santa Monica, California
UPMC Cancer Center
Pittsburgh, Pennsylvania
Tennessee Cancer Specialists - Biomedical Research
Knoxville, Tennessee
The University of Texas MD Anderson Cancer Center
Houston, Texas
Millennium Research & Clinical Development
Houston, Texas
Virginia Cancer Specialists, PC
Fairfax, Virginia
Institut Jules Bordet - Department of Institut Jules Bordet'
Anderlecht, Belgium
UZA - Oncology
Edegem, Belgium
Jessa Ziekenhuis Hospital
Hasselt, Belgium
Universitair Ziekenhuis Brussel - UZB
Jette, Belgium
UZ Leuven
Leuven, Belgium
CHU de Liège - PARENT
Liège, Belgium
CHU Angers - Hôpital Larrey - Service de Pneumologie
Angers, France
Centre Hospitalier Intercommunal de Créteil - Service de Pneumologie
Créteil, France
CHU Limoges - Hôpital Dupuytren - Unite d'Oncologie Thoracique et Cutanée
Limoges, France
Hôpital de la Timone - CPCEM CIC - Bat F 1er étage
Marseille, France
Hopital Arnaud de Villeneuve - Service de Pneumologie-Addictologie
Montpellier, France
Groupe Hospitalier Sud - Hôpital Haut-Lévêque - Unité d'Explorations Fonctionnelles Respiratoires
Pessac, France
ICO - Site René Gauducheau - Service d'Oncologie medicale
Saint-Herblain, France
Universitaetsklinikum Giessen und Marburg GmbH - Medizinische Klinik und Poliklinik III
Giessen, Germany
Universitaetsklinikum Leipzig AoeR - Med. Klinik u. Poliklinik I - Abt. Pneumologie
Leipzig, Germany
Sana Klinikum Offenbach GmbH - Medizinische Klinik IV
Offenbach, Germany
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS - U.O. Oncologia Medica
Bologna, Italy
IEO Istituto Europeo di Oncologia - Divisione Oncologia Medica
Milan, Italy
Ospedale San Raffaele - U.O. di Oncologia Medica
Milan, Italy
Istituto Nazionale Tumori Fondazione G. Pascale - Medical Oncology Thoraco-Pulmonary Department
Naples, Italy
Istituto Nazionale Tumori Regina Elena IRCCS - S.C. Oncologia Medica B
Roma, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica
Rome, Italy
Istituto Clinico Humanitas - U.O. di Oncologia Medica ed Ematologia
Rozzano, Italy
National Cancer Center Hospital
Chūōku, Japan
Kansai Medical University Hospital
Hirakata-shi, Japan
National Cancer Center Hospital East
Kashiwa-shi, Japan
Cancer Institute Hospital of JFCR
Kōtoku, Japan
Kurume University Hospital
Kurume-shi, Japan
Aichi Cancer Center Hospital
Nagoya, Japan
Kindai University Hospital
Osakasayama-shi, Japan
Kanagawa Cancer Center
Yokohama, Japan
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Severance Hospital, Yonsei University Health System - Division of Infectious Diseases
Seoul, South Korea
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.